Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Cytheris SA

Latest From Cytheris SA

TxCell names new CEO

Biotechnology company TxCell, which develops personalized cell-based immunotherapies using for chronic inflammatory and autoimmune diseases, has named Damian Marron chief executive officer. Prior to joining the Valbonne, France-based firm, Mr Marron was CEO of clinical stage biotechnology company Cytheris. Furthermore, from 2008-2012 he was CEO of Trophos. Under his tenure, Trophos spearheaded a group of major EU funded consortia of leading global experts and specialists working on a range of orphan diseases. Mr Marron succeeds Francois Meyer who has now been appointed executive chair of the TxCell's board of directors.

France

Damian Marron ditches Trophos for Cytheris top job

Damian Marron has left his CEO post at neurology- and cardiology-focused Trophos to take up the top job at privately-held biopharmaceutical company Cytheris. Mr Marron takes over from Dr François Thomas, who was acting president and CEO. Taking his place at Trophos is Christine Placet, who was previously the company's CFO.

COMP adopts positive opinion for 16 orphans

The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has adopted 16 positive opinions at its May meeting. Of these, six were adopted following a second discussion by the committee after the sponsoring company had responded to questions, and the other 10 were after their first consideration. The positive opinions constitute recommendations to the EMA, and are neither final decisions granting drugs EU orphan drug designation (these decisions are usually adopted within the space of a few weeks) nor are they recommendations for marketing authorisation.

Cardiovascular Dermatology

Private investment round-up: June 2010 – UK industry fails to worry Top Track

The UK's Sunday Times newspaper, in collaboration with FastTrack, last month published its annual Top Track 100 league table of the top 100 private companies in the UK with the greatest sales. Unsurprisingly, pharma and biotech companies were nowhere to be seen.

France Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register